Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS

Topics: 

Citation
Nauck MA, et al. Cardiovasc Diabetol 2019;18(1):116.